A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma. - Wikidata - wikimedia - TriplyDB

A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma.

A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma.

http://www.wikidata.org/entity/Q33621281

about

Comparison of single agent versus combined chemotherapy in previously treated patients with advanced urothelial carcinoma: a meta-analysis.Conditional Survival in de novo Metastatic Urothelial Carcinoma Personalized therapy for urothelial cancer: review of the clinical evidence.Effectiveness of capecitabine with or without docetaxel therapy for the treatment of patients with advanced urothelial carcinoma: a single-institution experience Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU).Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis

P2860

Q33431220-C3545EC3-288D-4585-82C4-E416DED9B32D Q35756105-305F7825-30F7-418A-BC29-709065C9609C Q36062762-2B35D633-7207-4B61-81CA-D3ADC1C804D2 Q37665453-7CC60213-E78C-4D33-A7BA-69FD28439955 Q38155201-901D3E5D-207C-4A24-8801-5EE77D9B6F1D Q38612831-3688E360-8A6B-43B7-86FC-0FF414E714CF Q38798645-8BC2E521-5C7E-41B6-BD07-7C6FC295AEF5 Q57073547-9F6AADD9-2D53-4D0E-9B18-DA4EDE315D9A

P2860

A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma.

http://www.wikidata.org/entity/Q33621281

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

A phase II study of docetaxel ...... tment of urothelial carcinoma.

@ast

A phase II study of docetaxel ...... tment of urothelial carcinoma.

@en

type

label

A phase II study of docetaxel ...... tment of urothelial carcinoma.

@ast

A phase II study of docetaxel ...... tment of urothelial carcinoma.

@en

prefLabel

A phase II study of docetaxel ...... tment of urothelial carcinoma.

@ast

A phase II study of docetaxel ...... tment of urothelial carcinoma.

@en

P1433

Q33621281-2A9B53A3-585C-46D1-A67C-02B9A2F4B0D9

P1476

Q33621281-446F05EC-8906-4E96-BC30-92F7F9B09421

P2093

Q33621281-96686802-0D85-4415-9B82-C6958E517219

Q33621281-B7DA4114-0853-4D9A-9B16-0078D1008D1B

P2860

Q33621281-0EE618F3-3E04-43EE-9EAB-ECAD6A6F8AC5

Q33621281-1BED637D-D044-4563-A000-535645DA2984

Q33621281-21C172B0-C517-406D-AEB6-8D9E0F4DC529

Q33621281-2A8168B8-6766-4BF2-8208-19D6EA9F0FFF

Q33621281-39A0D039-B14E-422D-AA2B-8E45527272AE

Q33621281-3C91EB2E-C9C6-4E19-BAB1-D4FCAAFB77AC

Q33621281-40E9DB57-61D2-4496-B70E-0BACDE26327D

Q33621281-485BFE73-E784-4FF8-8D23-1746482DF562

Q33621281-5988F079-C985-40B8-9ECD-8F67976174B8

Q33621281-5A50A043-7489-439C-A799-DC6448D21E7D

P304

Q33621281-4A0FCA41-087E-4C31-8C47-03B88C0AE5D8

P31

Q33621281-11A138DA-475D-4FAA-8EB0-0A7892E0A390

P356

Q33621281-0180E70B-F5BB-44E4-985C-B7C02B672EB7

P433

Q33621281-50695307-FE22-4F1A-BFC2-9C83B87A6EB3

P478

Q33621281-CC6F6446-79FC-4FA5-80D1-B533BF89E615

P577

Q33621281-5268214B-DA7B-47FF-A054-993D98B4B4FA

P5875

Q33621281-8D11CC32-894B-49AD-AE4F-7D0BAFC11671

P698

Q33621281-6BB10EE2-410D-41A3-844C-412FFEEC33A6

P932

Q33621281-A49CC9B2-DF6A-43C4-BB49-C52DF8A7E819

P356

P1433

P1476

A phase II study of docetaxel ...... tment of urothelial carcinoma.

@en

P2093

Lauren C Harshman

http://www.w3.org/2001/XMLSchema#string

Sandy Srinivas

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2008

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract.

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer.

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

The potential role of pemetrexed in gastrointestinal cancer.

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.

P304

321-326

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000230695

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26704101

http://www.w3.org/2001/XMLSchema#string

P698

19641314

http://www.w3.org/2001/XMLSchema#string

P932

2814022

http://www.w3.org/2001/XMLSchema#string